Prognostic Factors in Hormone Resistant Prostate Cancer
Author Information
Author(s): A. Berner, J.M. Nesland, H. Waehre, J. Silde, S.D. Fossa
Primary Institution: The Norwegian Radium Hospital and Institute for Cancer Research, The Norwegian Cancer Society, Norway
Hypothesis
The study aims to evaluate the prognostic factors in pre- and post-treatment specimens of hormone resistant prostatic adenocarcinoma.
Conclusion
Prostatic carcinoma shows significant dedifferentiation when it becomes hormone resistant, associated with increased p53 protein expression and decreased PSA immunoreactivity.
Supporting Evidence
- Significantly more post-treatment specimens expressed a high malignancy grade compared to pre-treatment specimens.
- p53 protein immunoreactivity increased significantly with disease progression.
- Tissue PSA immunoreactivity was reduced in post-treatment specimens.
Takeaway
This study looked at prostate cancer samples before and after hormone treatment and found that the cancer often becomes more aggressive and harder to treat after the treatment fails.
Methodology
The study compared pre- and post-treatment specimens from 47 patients, analyzing histological grade and immunoreactivity for various proteins.
Potential Biases
Potential bias due to the selection of only primary tumor biopsies and the limited number of core biopsies.
Limitations
Limited information about the extent of disease at diagnosis and the study's retrospective nature.
Participant Demographics
Patients were referred for palliative treatment between 1981 and 1992, median age at diagnosis was 66 years.
Statistical Information
P-Value
P:<0.0001, P:0.0003, P:0.006, P:0.011, P:0.46
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website